Form 4: Biogen Executive Rachid Izzar's Latest Stock Transactions
Insider Transaction Report
Biogen's Head of Global Product Strategy, Rachid Izzar, reported the vesting of restricted stock units and subsequent common stock transactions, including tax withholdings.
Summary
- Rachid Izzar, Biogen's Head of Global Product Strategy, reported multiple transactions on February 6, 2026, involving the vesting of Restricted Stock Units (RSUs) and subsequent acquisitions and dispositions of Biogen common stock.
- Izzar acquired a total of 6,889 shares of common stock through the vesting of RSUs (2,044 shares from a 2023 grant, 1,802 shares from a 2024 grant, and 3,043 shares from a 2025 grant).
- Concurrently, 2,038 shares of common stock were disposed of to cover tax withholding obligations at a price of $201.18 per share.
- Following these transactions, Izzar beneficially owns 11,011 shares of Biogen common stock directly.
- Additionally, Izzar holds 7,889 unvested Restricted Stock Units (1,802 RSUs from a 2024 grant and 6,087 RSUs from a 2025 grant) that are scheduled to vest in future installments.
- The total adjusted beneficial ownership of common stock reflects a prior transfer of shares to a former spouse pursuant to a Domestic Relations Order.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects the executive's continued accumulation of equity through compensation, despite some shares being sold for tax purposes and a prior transfer to a former spouse.
Positives
- Acquisition of 6,889 shares of Biogen common stock through the vesting of Restricted Stock Units, increasing direct ownership.
- Continued holding of 7,889 unvested Restricted Stock Units, indicating future potential equity accumulation.
Negatives
- Disposal of 2,038 shares of common stock at $201.18 per share to satisfy tax withholding obligations, reducing the net shares acquired.
- Prior adjustment to total beneficial ownership due to a transfer of shares to a former spouse pursuant to a Domestic Relations Order.
Industry Context
StockSavvy.ai notes that routine insider transactions like RSU vesting and subsequent tax-related dispositions are common occurrences in the biotechnology and pharmaceutical industry, reflecting standard executive compensation practices.
Related Party Transactions
- Transfer of shares to the reporting person's former spouse pursuant to a Domestic Relations Order, which adjusted the total beneficial ownership.
Stakeholder Impact
- Shareholders: Minor impact as these are routine compensation-related transactions for an executive.
- Reporting Person (Rachid Izzar): Increased direct ownership of common stock, reflecting compensation and continued alignment with company performance.
Next Steps
- Future vesting of 1,802 Restricted Stock Units on or around February 7, 2027.
- Future vesting of 3,043 Restricted Stock Units on or around February 6, 2027.
- Future vesting of 3,044 Restricted Stock Units on or around February 6, 2028.
Key Dates
| Date | Description |
|---|---|
| 02/08/2023 | Grant date for 2,044 Restricted Stock Units, which vested in three equal annual installments. |
| 02/07/2024 | Grant date for Restricted Stock Units, with 1,802 shares vesting on February 6, 2026, as part of three equal annual installments. |
| 02/06/2025 | Grant date for Restricted Stock Units, with 3,043 shares vesting on February 6, 2026, as part of three equal yearly installments. |
| 02/06/2026 | Date of reported transactions, including RSU vesting, common stock acquisition, and tax withholding dispositions. |
| 02/08/2026 | Expiration date for the Restricted Stock Units granted on February 8, 2023, indicating full vesting. |
| 02/10/2026 | Signature date of the Form 4 filing. |
| 02/07/2027 | Expiration date for the Restricted Stock Units granted on February 7, 2024, indicating final vesting installment. |
| 02/06/2028 | Expiration date for the Restricted Stock Units granted on February 6, 2025, indicating final vesting installment. |
Keywords
Biogen, BIIB, Rachid Izzar, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transaction, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.